North America Gene Synthesis Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 720.79 Million |
 Market Size (Forecast Year) |
USD 3,943.72 Million |
 CAGR |
% |
| Major Markets Players |
北美基因合成市场，按组件（合成器、消耗品、软件和服务）、基因类型（标准基因、表达基因、复杂基因及其他）、基因合成类型（基因库合成和定制基因合成）、应用（合成生物学、基因工程、疫苗设计、治疗抗体及其他）、方法（固相合成、基于芯片、DNA 合成和基于 PCR 的酶合成）、最终用户（学术和研究机构、诊断实验室、生物技术和制药公司及其他）分销渠道（直接招标、在线分销和第三方分销）划分，行业趋势及预测至 2029 年。
北美基因合成市场分析与洞察
基因合成是在实验室环境下利用合成生物学创造人工基因的过程。重组蛋白的生成是重组 DNA 技术的众多应用之一，其中基因合成正成为一种关键手段。传统的克隆和诱变方法正迅速被从头基因合成所取代，这种方法也能够生产没有模板的核酸。
北美基因合成市场预计将在 2022 年至 2029 年的预测期内增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场以 23.4% 的复合年增长率增长，预计将从 2021 年的 7.2079 亿美元达到 2029 年的 39.4372 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 (可定制为 2019-2015) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按组件（合成器、消耗品和软件和服务）、基因类型（标准基因、表达基因、复杂基因和其他）、基因合成类型（基因库合成和定制基因合成）、应用（合成生物学、基因工程、疫苗设计、治疗抗体和其他）、方法（固相合成、基于芯片、DNA合成和基于PCR的酶合成）、最终用户（学术和研究机构、诊断实验室、生物技术和制药公司等）分销渠道（直接招标、在线分销和第三方分销）。 |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
Twist Bioscience、OriGene Technologies、Integrated DNA Technologies, Inc.（丹纳赫集团的子公司）、Ansa Biotechnologies, Inc.、Thermo Fisher Scientific、Genescript、Synbio Technologies、Proteogenix、Bio Basic Inc.、Ginkgo Bioworks、Evonetix、ProMab Biotechnologies, Inc.、Azenta US, Inc. 等。 |
市场定义
基因合成是指 DNA 链逐个碱基的化学合成。与细胞内或通过聚合酶链式反应(PCR) 进行的 DNA 复制不同，基因合成不需要模板链。相反，基因合成涉及逐步将核苷酸添加到单链分子中，然后将其作为创建互补链的模板。基因合成是合成生物学的基础技术。
基因合成市场动态
本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：
驱动程序
- 慢性传染病患病率上升
由于全球传染病的流行率不断上升，细菌和病毒性疾病正在迅速蔓延。因此，对新型有效疗法的需求也随之增加，以对抗这些致命疾病。这些疾病可以使用化学药物和生物疗法（包括基因疗法）治愈。应用基因组学增强了传染病和地方病的管理。它还使我们能够了解新出现的耐药性并确定新疗法和疫苗的目标。对于传染病的治疗，基因疗法吸引了许多研究人员，因为它可以通过重组 DNA 技术、DNA 和 RNA 核酶以及单链抗体进行治疗。
随着全球慢性传染病的发病率不断上升，对疫苗和有效基因治疗的需求也随之上升，对新基因的需求也随之增加，这些新基因在研究活动以及药物和疫苗制造中具有重要应用。因此，传染病的发病率不断上升正在推动基因合成市场的增长。
- 基因治疗应用日益增多
基因治疗是一种先进的技术，包括使用多个基因来预防特定疾病类型。该技术涉及将基因插入患者细胞，而不是药物和手术。由于对新颖且持久的治疗效果的需求增加，基因治疗的采用正在增加。基因治疗需要合成基因构建体以及其他基因产品，以加速基因治疗的发展。由于遗传疾病的增加，对适当治疗的需求是一个主要因素，借助基因治疗，可以治愈特定疾病类型。
由于需求增加，领导者不断专注于生产基因治疗产品、获得批准和营销授权。
为了给患者提供高质量的生活，人们对救命药物和疗法的需求巨大。这些不断增长的患者数量在很大程度上取决于可用的基因疗法来实现适当的治愈。要制造基因疗法，需要合成和新基因，这可以通过基因合成技术实现。因此，基因疗法的日益普及有望成为基因合成市场的驱动力。
- 合成生物学的扩展
将工程原理融入生物学被称为合成生物学。DNA 基因组可以在合成生物学的帮助下重新组装，因为它涉及通过将 DNA 与基因组结合来进行 DNA 的化学合成。通过结合使用基因合成服务、软件和消耗品，可以在短时间内构建寡核苷酸。随着全球对合成生物学产品的需求不断增加，基因合成产品和服务也在不断增加。
因此，由于其有效和创新的产品，全球对合成生物学产品的需求正在增加，这有望成为基因合成市场的驱动因素。
机会
- 医疗支出增加
随着各国人民可支配收入的提高，全球医疗支出也随之增加。此外，为满足人口需求，政府机构和医疗机构正采取主动行动，加快医疗支出。
此外，主要市场参与者采取的战略举措将为 2022-2029 年预测期内的医疗器械测试市场提供结构完整性和未来机遇。
限制/挑战
- 生产过程中的技术限制
然而，某些地区基因合成技术的壁垒和基因合成过程的高成本可能会阻碍基因合成程序的发展，从而阻碍市场的增长。此外，医疗技术行业的激烈竞争和海外资格认证的漫长准备时间也可能成为市场增长的挑战因素
本基因合成市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地化市场参与者的影响，分析了新兴收入来源方面的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地理扩展、市场技术创新
近期发展
- 2020 年 12 月，Twist Bioscience 推出了可克隆的基因片段，以完善基因的供应。推出的片段可以与或不与接头一起使用，以构建完美的克隆。可克隆的基因片段与蛋白质表达途径、酶工程和基因表达等兼容。
- 根据 ACS 期刊发表的一篇文章，2020 年全球报告的癌症新发病例估计为 1930 万例，癌症死亡病例近 1000 万例。这表明癌症覆盖率并不理想，迫切需要在全球范围内实施高覆盖率
北美基因合成市场范围
北美基因合成市场细分为成分、基因类型、基因合成类型、应用、方法、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
成分
- 合成器
- 耗材
- 软件和服务
根据组成部分，北美基因合成市场分为合成器、消耗品以及软件和服务。
基因类型
- 标准基因
- 表达基因
- 复合基因
- 其他的
根据基因类型，北美基因合成市场分为标准基因、表达基因、复杂基因和其他。
基因合成类型
- 基因文库合成
- 定制基因合成
根据基因合成类型，北美基因合成市场分为基因合成库和定制基因合成。
应用
- 合成生物学，
- 基因工程，
- 疫苗设计，
- 治疗性抗体
- 其他的
根据应用，北美基因合成市场细分为合成生物学、基因工程、疫苗设计、治疗性抗体等。
方法
- 固相合成，
- 基于芯片的 DNA 合成
- 基于PCR的酶合成
根据方法，北美基因合成市场分为固相合成、基于芯片的 DNA 合成和基于 PCR 的酶合成。
最终用户
- 学术及研究机构，
- 诊断实验室，
- 生物科技与制药公司
- 其他的
根据最终用户，北美基因合成市场分为学术和研究机构、诊断实验室、生物技术和制药公司等。
分销渠道
- 直接招标
- 网上分销
- 第三方分销商
根据分销渠道，北美基因合成市场分为直接招标、在线分销和第三方分销商。
基因合成市场区域分析/见解
对基因合成市场进行了分析，并按国家、成分、基因类型、基因合成类型、应用、方法、最终用户和分销渠道提供了市场规模洞察和趋势，如上所述。
美国在市场份额和市场收入方面占据北美基因合成市场的主导地位，并将在预测期内继续保持主导地位。这是由于该地区对基因合成过程的验证和确认需求不断增加，而快速的研究发展正在推动市场的发展。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场法规变化。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。
竞争格局和基因合成市场份额分析
基因合成市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上数据点仅与专注于共济失调市场的公司有关。
基因合成市场的一些主要参与者包括 ATDBio Ltd（Biotage 的子公司）、General Biosystems, Inc.、MACROGEN CO., LTD.、Boster Biological Technology、Creative Biogene、Bioneer Pacific、exonbio、trenzyme GmbH、Twist Bioscience、BioCat GmbH（AddLife AB 的子公司）、OriGene Technologies, Inc.、Integrated DNA Technologies, Inc.（Danaher Corporation 的子公司）、Eurofins Scientific、NZYTech, Lda. - Genes and Enzymes、Ansa Biotechnologies, Inc.、Thermo Fisher Scientific、Genescript、Synbio Technologies、Proteogenix、Bio Basic Inc.、ATG: biosynthetic GmbH、Merck KGaA、Kaneka Eurogentec SA、Ginkgo Bioworks、Bbi-lifesciences、Evonetix、ProMab Biotechnologies, Inc.、GCC Biotech (INDIA) Pvt。 Ltd.、CSBio、Azenta US, Inc. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA GENE SYNTHESIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 COMPONENT SEGMENT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 THE CATEGORY VS TIME GRID
2.13 SECONDARY SOURCES
2.14 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 NORTH AMERICA GENE SYNTHESIS MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED PREVALENCE OF CHRONIC INFECTIOUS DISEASES
6.1.2 RISING ADOPTION OF GENE THERAPY
6.1.3 EXPANSION OF SYNTHETIC BIOLOGY
6.1.4 RISING INTEREST OF GENE SYNTHESIS IN THE FIELD OF MOLECULAR BIOLOGY
6.2 RESTRAINTS
6.2.1 LACK OF TRAINED PROFESSIONALS
6.2.2 ETHICAL ISSUES
6.2.3 LONG APPROVAL PROCESS
6.3 OPPORTUNITIES
6.3.1 RISE IN HEALTHCARE EXPENDITURE
6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS
6.3.3 RISING DEMAND FOR CUSTOMIZED MEDICATIONS
6.4 CHALLENGES
6.4.1 TECHNICAL LIMITATIONS ACROSS PRODUCTION PROCESS
6.4.2 LACK OF WELL DEFINED PATENT SYSTEM
7 NORTH AMERICA GENE SYNTHESIS MARKET, BY COMPONENT
7.1 OVERVIEW
7.2 SOFTWARE & SERVICES
7.3 CONSUMABLES
7.3.1 REAGENTS
7.3.2 ASSAYS
7.3.3 PROBES & DYES
7.3.4 OTHERS
7.4 SYNTHESIZER
7.4.1 COLUMN-BASED SYNTHESIZERS
7.4.2 MICROARRAY-BASED SYNTHESIZERS
8 NORTH AMERICA GENE SYNTHESIS MARKET, BY GENE TYPE
8.1 OVERVIEW
8.2 STANDARD GENE
8.3 COMPLEX GENE
8.4 EXPRESS GENE
8.5 OTHERS
9 NORTH AMERICA GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE
9.1 OVERVIEW
9.2 CUSTOM GENE SYNTHESIS
9.2.1 STANDARD GENE
9.2.2 COMPLEX GENE
9.2.3 EXPRESS GENE
9.2.4 OTHERS
9.3 GENE LIBRARY SYNTHESIS
9.3.1 STANDARD GENE
9.3.2 COMPLEX GENE
9.3.3 EXPRESS GENE
9.3.4 OTHERS
10 NORTH AMERICA GENE SYNTHESIS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 SYNTHETIC BIOLOGY
10.2.1 CUSTOM GENE SYNTHESIS
10.2.2 GENE LIBRARY SYNTHESIS
10.3 GENETIC ENGINEERING
10.3.1 CUSTOM GENE SYNTHESIS
10.3.2 GENE LIBRARY SYNTHESIS
10.4 THERAPEUTIC ANTIBODIES
10.4.1 CUSTOM GENE SYNTHESIS
10.4.2 GENE LIBRARY SYNTHESIS
10.5 VACCINE DESIGN
10.5.1 CUSTOM GENE SYNTHESIS
10.5.2 GENE LIBRARY SYNTHESIS
10.6 OTHERS
11 NORTH AMERICA GENE SYNTHESIS MARKET, BY METHOD
11.1 OVERVIEW
11.2 PCR-BASED ENZYME SYNTHESIS
11.3 CHIP-BASED DNA SYNTHESIS
11.4 SOLID BASED SYNTHESIS
12 NORTH AMERICA GENE SYNTHESIS MARKET, BY END USER
12.1 OVERVIEW
12.2 ACADEMIC & RESEARCH INSTITUTE
12.3 BIOTECH & PHARMACEUTICAL COMPANIES
12.4 DIAGNOSTIC LABORATORIES
12.5 OTHERS
13 NORTH AMERICA GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 ONLINE DISTRIBUTION
13.4 THIRD PARTY DISTRIBUTORS
14 NORTH AMERICA GENE SYNTHESIS MARKET,BY REGION
14.1 U.S.
14.2 CANADA
14.3 MEXICO
15 NORTH AMERICA GENE SYNTHESIS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER)
17.1.1 COMPANY SNAPSHOT
17.1.2 COMPANY SHARE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENTS
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 EUROFINS SCIENTIFIC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 SERVICE PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 MERCK KGAA
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 KANEKA EUROGENTEC S.A.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ANSA BIOTECHNOLOGIES, INC
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 ATG:BIOSYNTHETICS GMBH
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 AZENTUS US, INC (2021)
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BIO BASIC INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 BOSTER BIOLOGICAL TECHNOLOGY
17.10.1 COMPANY SNAPSHOT
17.10.2 SERVICE PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 CSBIO
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 CREATIVE BIOGENE
17.12.1 COMPANY SNAPSHOT
17.12.2 RODUCTPORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 EVONETIX
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 EXONBIO
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 GINKGO BIOWORKS (2021)
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 GENERAL BIOSYSTEMS INC
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 GENSCRIPT
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENTS
17.18 MACROGEN CO., LTD. (A SUBSIDIARY OF MACROGEN, INC)
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 NZYTECH, LDA. - GENES AND ENZYMES.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 ORIGENE TECHNOLOGIES, INC
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 PROMAB BIOTECHNOLOGIES
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 PROTEOGENIX
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENTS
17.23 SYNBIO TECHNOLOGIES
17.23.1 COMPANY SNAPSHOT
17.23.2 PRODUCT PORTFOLIO
17.23.3 RECENT DEVELOPMENTS
17.24 TWIST BIOSCIENCE
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA GENE SYNTHESIS MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA CONSUMABLES IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA SYNTHESIZER IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA CUSTOM GENE SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA GENE LIBRARY SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA GENE SYNTHESIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA SYNTHETIC BIOLOGY IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA GENETIC ENGINEERING IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA THERAPEUTIC ANTIBODIES IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA VACCINE DESIGN IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA GENE SYNTHESIS MARKET, BY METHOD, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA GENE SYNTHESIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 16 U.S. GENE SYNTHESIS MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 17 U.S. CONSUMABLES IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 U.S. SYNTHESIZER IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 U.S. GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 20 U.S. GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 21 U.S. CUSTOM GENE SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 22 U.S. GENE LIBRARY SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 23 U.S. GENE SYNTHESIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 24 U.S. SYNTHETIC BIOLOGY IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 25 U.S. GENETIC ENGINEERING IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 26 U.S. THERAPEUTIC ANTIBODIES IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 27 U.S. VACCINE DESIGN IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 28 U.S. GENE SYNTHESIS MARKET, BY METHOD, 2020-2029 (USD MILLION)
TABLE 29 U.S. GENE SYNTHESIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 U.S. GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 CANADA GENE SYNTHESIS MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 32 CANADA CONSUMABLES IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 CANADA SYNTHESIZER IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 34 CANADA GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 35 CANADA GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 36 CANADA CUSTOM GENE SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 37 CANADA GENE LIBRARY SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 38 CANADA GENE SYNTHESIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 39 CANADA SYNTHETIC BIOLOGY IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 40 CANADA GENETIC ENGINEERING IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 41 CANADA THERAPEUTIC ANTIBODIES IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 42 CANADA VACCINE DESIGN IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 43 CANADA GENE SYNTHESIS MARKET, BY METHOD, 2020-2029 (USD MILLION)
TABLE 44 CANADA GENE SYNTHESIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 45 CANADA GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 46 MEXICO GENE SYNTHESIS MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 47 MEXICO CONSUMABLES IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 MEXICO SYNTHESIZER IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 MEXICO GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 50 MEXICO GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 51 MEXICO CUSTOM GENE SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 52 MEXICO GENE LIBRARY SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 53 MEXICO GENE SYNTHESIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 54 MEXICO SYNTHETIC BIOLOGY IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 55 MEXICO GENETIC ENGINEERING IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 56 MEXICO THERAPEUTIC ANTIBODIES IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 57 MEXICO VACCINE DESIGN IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION)
TABLE 58 MEXICO GENE SYNTHESIS MARKET, BY METHOD, 2020-2029 (USD MILLION)
TABLE 59 MEXICO GENE SYNTHESIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 60 MEXICO GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA GENE SYNTHESIS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA GENE SYNTHESIS MARKET: GEOGRAPHIC SCOPE
FIGURE 3 NORTH AMERICA GENE SYNTHESIS MARKET: DATA TRIANGULATION
FIGURE 4 NORTH AMERICA GENE SYNTHESIS MARKET: SNAPSHOT
FIGURE 5 NORTH AMERICA GENE SYNTHESIS MARKET: BOTTOM UP APPROACH
FIGURE 6 NORTH AMERICA GENE SYNTHESIS MARKET: TOP DOWN APPROACH
FIGURE 7 NORTH AMERICA GENE SYNTHESIS MARKET: INTERVIEWS BY REGION AND DESIGNATION
FIGURE 8 NORTH AMERICA GENE SYNTHESIS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA GENE SYNTHESIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA GENE SYNTHESIS MARKET: END USER COVERAGE GRID
FIGURE 11 NORTH AMERICA GENE SYNTHESIS MARKET: THE CATEGORY VS TIME GRID
FIGURE 12 NORTH AMERICA GENE SYNTHESIS MARKET SEGMENTATION
FIGURE 13 GROWING PREVALENCE OF CHRONIC INFECTIOUS DISEASES , EXPANSION OF SYNTHETIC BIOLOGY AND RISING ADOPTION OF GENE THERAPY ARE EXPECTED TO DRIVE THE MARKET FOR NORTH AMERICA GENE SYNTHESIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 SYNTHESIZER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GENE SYNTHESIS MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA GENE SYNTHESIS MARKET
FIGURE 16 NORTH AMERICA GENE SYNTHESIS MARKET: BY COMPONENT, 2021
FIGURE 17 NORTH AMERICA GENE SYNTHESIS MARKET: BY COMPONENT, 2022-2029 (USD MILLION)
FIGURE 18 NORTH AMERICA GENE SYNTHESIS MARKET: BY COMPONENT, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA GENE SYNTHESIS MARKET: BY COMPONENT, LIFELINE CURVE
FIGURE 20 NORTH AMERICA GENE SYNTHESIS MARKET: BY GENE TYPE, 2021
FIGURE 21 NORTH AMERICA GENE SYNTHESIS MARKET: BY GENE TYPE, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA GENE SYNTHESIS MARKET: BY GENE TYPE, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA GENE SYNTHESIS MARKET: BY GENE TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA GENE SYNTHESIS MARKET: BY GENE SYNTHESIS TYPE, 2021
FIGURE 25 NORTH AMERICA GENE SYNTHESIS MARKET: BY GENE SYNTHESIS TYPE, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA GENE SYNTHESIS MARKET: BY GENE SYNTHESIS TYPE, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA GENE SYNTHESIS MARKET: BY GENE SYNTHESIS TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA GENE SYNTHESIS MARKET: BY APPLICATION, 2021
FIGURE 29 NORTH AMERICA GENE SYNTHESIS MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 30 NORTH AMERICA GENE SYNTHESIS MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA GENE SYNTHESIS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 32 NORTH AMERICA GENE SYNTHESIS MARKET: BY METHOD, 2021
FIGURE 33 NORTH AMERICA GENE SYNTHESIS MARKET: BY METHOD, 2022-2029 (USD MILLION)
FIGURE 34 NORTH AMERICA GENE SYNTHESIS MARKET: BY METHOD, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA GENE SYNTHESIS MARKET: BY METHOD, LIFELINE CURVE
FIGURE 36 NORTH AMERICA GENE SYNTHESIS MARKET: BY END USER, 2021
FIGURE 37 NORTH AMERICA GENE SYNTHESIS MARKET: BY END USER, 2021-2029 (USD MILLION)
FIGURE 38 NORTH AMERICA GENE SYNTHESIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA GENE SYNTHESIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA GENE SYNTHESIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 NORTH AMERICA GENE SYNTHESIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 NORTH AMERICA GENE SYNTHESIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 NORTH AMERICA GENE SYNTHESIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA GENE SYNTHESIS MARKET: SNAPSHOT (2021)
FIGURE 45 NORTH AMERICA GENE SYNTHESIS MARKET: BY COUNTRY (2021)
FIGURE 46 NORTH AMERICA GENE SYNTHESIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 NORTH AMERICA GENE SYNTHESIS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 NORTH AMERICA GENE SYNTHESIS MARKET: BY COMPONENT (2022-2029)
FIGURE 49 NORTH AMERICA GENE SYNTHESIS MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
